This is Data Driven, a new series that explore our nation’s health agencies’ publicly available data. This data, which is comprised of searchable online databases and files, presents a unique opportunity to analyze information on broad health care topics. We thought it would be interesting to explore data from agencies whose work most closely…
In 2012, the Breakthrough Therapy Designation was signed into law. Four years later, Friends of Cancer Research (Friends) continues to steward the program that the organization developed by working closely with FDA and other stakeholders to ensure the program is as efficient and effective as possible. As part of this stewardship, Friends hosted a Senate briefing…
Congress Must Pass 21st Century Cures Act Now This is an incredibly exciting time in biomedical research. New discoveries are announced almost every week that bring us closer to managing cancer and other life-threatening diseases. We are attacking these illnesses at the molecular and genetic levels. In cancer, for example, scientists have gone beyond treating…
It’s been a busy spring for drug development. We’ve had leadership changes at FDA, legislative pushes in Congress, and a host of conferences and meetings to present and advance ideas from the cutting edge of science and policy. It’s a lot of keep up with. Here are the biggest stories from the last few months.…
This Friday, the U.S. House will vote on the 21st Century Cures Act. The Act creates a cohesive, efficient, effective, and patient-centered path to cures. The 21st Century Cures Act, a substantial piece of legislation that touches on all aspects of medical innovation – from basic research to regulation, from biomarkers to patient data –…
Margaret Hamburg has been the Commissioner of the Food and Drug Administration (FDA) since 2009. In the below entry, part 2 of 2, Dr. Hamburg discusses her experience as Commissioner, her perspective on the FDA, and her advice for future FDA Commissioners. The interview was conducted by Ryan Hohman, Managing Director, Policy & Public Affairs of Friends…
Margaret Hamburg has been the Commissioner of the Food and Drug Administration (FDA) since 2009. In the below entry, part 1 of 2, Dr. Hamburg discusses critical issues in FDA drug policy, including the use of surrogate endpoints and the development of new regulatory tools. The interview was conducted by Ryan Hohman, Managing Director, Policy & Public…
A unique public-private collaboration among the National Cancer Institute (NCI), part of the National Institutes of Health, SWOG Cancer Research, Friends of Cancer Research (Friends), the Foundation for the National Institutes of Health (FNIH), the US Food and Drug Administration (FDA), five pharmaceutical companies (Amgen, Genentech, Pfizer, AstraZeneca, and AstraZeneca’s global biologics R&D arm, MedImmune),…
